Portal de Periódicos da CAPES

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

2022; Multidisciplinary Digital Publishing Institute; Volume: 11; Issue: 7 Linguagem: Inglês

10.3390/jcm11071829

2077-0383

Stijn Muselaers, Selçuk Erdem, Riccardo Bertolo, Alexandre Ingels, Önder Kara, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Michele Marchioni, Umberto Carbonara, Laura Marandino, Daniele Amparore, Riccardo Campi,

Prostate Cancer Diagnosis and Treatment

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.